Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.18 USD
-1.25 (-2.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $59.17 -0.01 (-0.02%) 7:26 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.18 USD
-1.25 (-2.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $59.17 -0.01 (-0.02%) 7:26 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag
by Zacks Equity Research
Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.
Compared to Estimates, Halozyme Therapeutics (HALO) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
by Zacks Equity Research
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now
by Zacks Equity Research
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.7% in Halozyme Therapeutics (HALO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.